Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases最新文献

{"title":"[Primary α-fetoprotein positive hepatoid adenocarcinoma of the lung: a case report].","authors":"K Zhang,&nbsp;Q Liu,&nbsp;B Liu,&nbsp;D Lin","doi":"10.3760/cma.j.cn112147-20221103-00874","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20221103-00874","url":null,"abstract":"<p><p>This paper reports the data of a patient who was admitted to hospital for \"cough with blood in sputum for 6 months\" and diagnosed with α-fetoprotein(AFP) positive primary hepatoid adenocarcinoma of the lung. The patient was an 83-year-old male with a history of smoking for more than 60 years. Tumor indicators of patients were: AFP>3 000 ng/ml, carcinoembryonic antigen(CEA) 31.5 ng/ml, CA724 46.90 U/ml, Cyfra21-1 10.20 ng/ml, NSE 18.50 ng/ml, and the pathological findings of percutaneous lung biopsy showed that poorly differentiated cancer with significant necrosis. Combined with the results of immunohistochemistry and clinical laboratory examination, it is considered as metastatic hepatocellular carcinoma. PET-CT showed that FDG metabolism of multiple lymph nodes in the right lower lung, part of the pleura and mediastinum was increased, and the FDG metabolism in the liver or other systems/tissues was normal. Based on these results, it was diagnosed as AFP positive primary hepatoid adenocarcinoma of the lung, and the tumor stage was T4N3M1a(IVA). Through the data of the patient and the existing literature and reviews, we can get the tumor characteristics, diagnosis, treatment and prognosis of HAL, and improve the level of diagnosis and treatment of HAL by clinicians.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"700-707"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9752048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress of thrombolytic therapy for high risk and intermediate-high risk pulmonary thromboembolism].","authors":"J J Yang,&nbsp;Y Zhang,&nbsp;Z G Zhai,&nbsp;Y H Yang","doi":"10.3760/cma.j.cn112147-20221102-00866","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20221102-00866","url":null,"abstract":"<p><p>Acute pulmonary thromboembolism (PTE) is a highly fatal disease. Fibrinolytic therapy can rapidly improve pulmonary hemodynamics and is an important life-saving treatment. How to screen patients who may benefit from thrombolytic therapy and how to reduce the complications of major bleeding are still the focus of PTE treatment. In addition, as our understanding of post-PE syndrome (PPES) has improved, much attention has been paid to whether thrombolytic therapy has any benefit in preventing PPES. This article reviewed the research progress of early risk stratification and prognosis assessment, early major bleeding risk assessment, thrombolytic drug dose reduction, interventional thrombolysis and the long-term prognosis of PTE thrombolysis in recent years.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"720-725"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Risk factors for pulmonary atelectasis in adults with tracheobronchial tuberculosis].","authors":"Q Chen,&nbsp;G H Wu,&nbsp;T Huang,&nbsp;L P Zou,&nbsp;L Liang,&nbsp;S X Wu,&nbsp;S J Tang,&nbsp;X L Lu,&nbsp;J Y Sun,&nbsp;L Dai,&nbsp;W He","doi":"10.3760/cma.j.cn112147-20230120-00032","DOIUrl":"10.3760/cma.j.cn112147-20230120-00032","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the risk factors for pulmonary atelectasis in adults with tracheobronchial tuberculosis(TBTB). <b>Methods:</b> Clinical data of adult patients (≥18 years old) with TBTB from February 2018 to December 2021 in Public Health Clinical Center of Chengdu were retrospectively analyzed. A total of 258 patients were included, with a male to female ratio of 1∶1.43. The median age was 31(24, 48) years. Clinical data including clinical characteristics, previous misdiagnoses/missed diagnoses before admission, pulmonary atelectasis, the time from symptom onset to atelectasis and bronchoscopy, bronchoscopy and interventional treatment were collected according to the inclusion and exclusion criteria. Patients were divided into two groups according to whether they had pulmonary atelectasis. Differences between the two groups were compared. Binary logistic regression was used to analyze the risk factors for pulmonary atelectasis. <b>Results:</b> The prevalence of pulmonary atelectasis was 14.7%, which was most common in the left upper lobe (26.3%). The median time from symptom onset to atelectasis was 130.50(29.75,358.50)d, and the median time from atelectasis to bronchoscopy was 5(3,7)d. The median age, the proportion of misdiagnosis of TBTB before admission, and the time from symptom onset to bronchoscopy in the atelectasis group were higher than those without atelectasis, and the proportion of receiving bronchoscopy examination and interventional therapy previously, and the proportion of pulmonary cavities were lower than those without atelectasis (all <i>P</i><0.05). The proportions of cicatrices stricture type and lumen occlusion type in the atelectasis group were higher than those without atelectasis, while the proportions of inflammatory infiltration type and ulceration necrosis type were lower than those without atelectasis (all <i>P</i><0.05). Older age (<i>OR</i>=1.036, 95%<i>CI</i>: 1.012-1.061), previous misdiagnosis(<i>OR</i>=2.759, 95%<i>CI</i>: 1.100-6.922), longer time from symptom onset to bronchoscopy examination (<i>OR</i>=1.002, 95%<i>CI</i>: 1.000-1.005) and cicatrices stricture type (<i>OR</i>=2.989, 95%<i>CI</i>: 1.279-6.985) were independent risk factors for pulmonary atelectasis in adults with TBTB (all <i>P</i><0.05). Of the patients with atelectasis who underwent bronchoscopy interventional therapy, 86.7% had lung reexpansion or partial reexpansion. <b>Conclusions:</b> The prevalence of pulmonary atelectasis is 14.7% in adult patients with TBTB. The most common site of atelectasis is left upper lobe. The TBTB type of lumen occlusion is complicated by pulmonary atelectasis in 100% of cases. Being older, misdiagnosed as other diseases, longer time from onset of symptoms to bronchoscopy examination, and being the cicatrices stricture type are factors for developing pulmonary atelectasis. Early diagnosis and treatment are needed to reduce the incidence of pulmonary atelectasis and increase the rate of p","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"674-679"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress of cell therapy in hereditary pulmonary alveolar proteinosis].","authors":"M N Zhang,&nbsp;J Jin,&nbsp;X Y Song,&nbsp;S Y Li","doi":"10.3760/cma.j.cn112147-20230107-00008","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20230107-00008","url":null,"abstract":"<p><p>Hereditary pulmonary alveolar proteinosis (hPAP) is a rare interstitial lung disease caused by mutation in CSF2RA/CSF2RB, characterized by the deposition of pulmonary surfactant due to the alveolar macrophage dysfunction. The whole lung lavage can effectively alleviate the symptoms but is associated with potential complications. Cell therapy is a novel approach with advances that provide a new therapeutic strategy for the treatment of hPAP.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"730-734"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9755107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A brief history of <i>Chinese Journal of Tuberculosis and Respiratory Diseases</i> on its 70th anniversary].","authors":"","doi":"10.3760/cma.j.cn112147-20220908-00748","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20220908-00748","url":null,"abstract":"<p><p>In 2023, the <i>Chinese Journal of Tuberculosis and Respiratory Diseases</i> celebrates its 70th anniversary. This article reviewed the history of this journal over the past 70 years since its inception. Formerly known as <i>the Chinese Journal of Tuberculosis</i>, the peer-reviewed scientific periodical was established on July 1^st, 1953 with the approval of Chinese Medical Association. During the period from 1953 to 1966, the journal went through its initial growth and cooperation phases, publishing a number of studies on the diagnosis, treatment as well as prevention and control of tuberculosis, leading the academic frontier of tuberculosis prevention and treatment nationwide. From 1978 to 1987, the journal was renamed as <i>the Chinese Journal of Tuberculosis and Respiratory System Diseases</i>, and its focus shifted from tuberculosis alone to a broader field of respiratory diseases. In 1987, the journal assumed its current name <i>the Chinese Journal of Tuberculosis and Respiratory Diseases.</i> Since then, the journal has been sponsored and published by Chinese Medical Association, and jointly managed by the Chinese Tuberculosis Association and Chinese Respiratory Diseases Association, both branches of the Chinese Medical Association. As of now, the journal has become the most sought after and cited peer-reviewed periodical in the field of tuberculosis and respiratory diseases in China. This article reviewed the journal's historical development with emphasis on some of the key events along the way, such as the name change events, the change of address of the editorial board, the evolution of the journal format, the change of frequency and interval of journal publication, brief biography of all the editors-in-chief, achievements and honors ever won and bestowed upon the journal. The article also discussed some of the key experiences gained along the historical development of the journal, as well as their significance in promoting and facilitating the development and exchange in the field of tuberculosis, respiratory diseases, and multidisciplinary diagnosis and treatment of these health conditions, and provided an outlook on the future of the journal in the new historical period of high quality development.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"651-657"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical analysis of 66 cases of pseudo fever].","authors":"H X Lu,&nbsp;X Chen,&nbsp;Y Z Zhai,&nbsp;H J Xiao,&nbsp;G Liu","doi":"10.3760/cma.j.cn112147-20221201-00943","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20221201-00943","url":null,"abstract":"<p><p>Some patients who present with a \"fever\" may only have a localized increase in body surface temperature, while their core body temperature remains normal. This phenomenon is commonly referred to as pseudo fever. A retrospective analysis of clinical data from January 2013 to January 2020 at our fever clinic showed that 66 adolescents were diagnosed with pseudo fever. These patients typically showed a gradual increase in axillary temperature after their cold symptoms had disappeared. Most patients reported no significant complaints other than mild dizziness. Laboratory tests showed no significant abnormalities, and antipyretics were ineffective in lowering their body temperature. Pseudo fever is a relatively independent clinical phenomenon that is distinct from functional fever or simulated fever, and its underlying mechanism remains to be studied.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"697-699"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Evaluation of the performance of InnowaveDX MTB/RIF for the detection of <i>Mycobacterium tuberculosis</i> complex and rifampicin resistance].","authors":"Y P Wang,&nbsp;Y H Tan,&nbsp;X Li,&nbsp;J Wang,&nbsp;C G Chen,&nbsp;J Xu,&nbsp;J Xiang","doi":"10.3760/cma.j.cn112147-20221104-00877","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20221104-00877","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the performance of <i>Mycobacterium tuberculosis</i> and rifampicin resistance mutation detection kit (InnowaveDX MTB/RIF, referred to as \"InnowaveDX\") in diagnosing tuberculosis and rifampicin resistance using sputum samples. <b>Methods:</b> From June 19, 2020 to May 16, 2022, patients with suspected tuberculosis were prospectively and consecutively enrolled in Hunan Provincial Tuberculosis Prevention and Control Institute, Henan Provincial Hospital of Infectious Diseases and Wuhan Jinyintan Hospital. A total of 1 328 patients with suspected tuberculosis were finally included. According to the inclusion and exclusion criteria, 1 035 pulmonary tuberculosis patients (357 were confirmed tuberculosis cases and 678 were clinically diagnosed tuberculosis cases) and 180 non-tuberculosis patients were finally included. Sputum samples were collected from all patients for routine sputum smear acid-fastness tests, mycobacterial culture and drug susceptibility testing. Moreover, the diagnostic value of Xpert^®MTB/RIF (referred to as \"Xpert\") and InnowaveDXin detecting tuberculosis and rifampicin resistance was evaluated. Clinical diagnosis and culture results of <i>Mycobacterium tuberculosis</i> were used as reference standards to assess tuberculosis diagnosis, and phenotypic drug sensitivity and Xpert were used as reference standards to assess rifampicin resistance. The sensitivity, specificity, positive predictive value and negative predictive value of the two methods for tuberculosis diagnosis and rifampicin resistance were analyzed. The consistency of the two techniques was analyzed usingkappa test. <b>Results:</b> Taking clinical diagnosis as the reference standard, the detection sensitivity of InnowaveDX [58.0% (600/1 035)] was higher than that of Xpert [51.7% (535/1 035)] in 1035 patients with pulmonary tuberculosis, and the difference was statistically significant (<i>P</i><0.001). In 270 pulmonary tuberculosis patients with culture-positive pulmonary tuberculosis identified as <i>M.tuberculosis</i>-complex, the positive rates of InnowaveDX and Xpert were both high [99.6%(269/270)and 98.2%(265/270), respectively] and there was no statistical difference. In culture-negative patients with pulmonary tuberculosis, the sensitivity of InnowaveDX was 38.8% (198/511), which was higher than that of Xpert (29.4%, 150/511), and the difference was statistically significant (<i>P</i><0.001). Taking phenotypic drug-susceptibility testing (DST) as reference, the sensitivity of InnowaveDX to rifampicin resistance was 99.0% (95%<i>CI</i>: 94.7%-100.0%) and the specificity was 94.0%(95%<i>CI</i>: 88.5%-97.4%). With Xpert as the reference, the sensitivity and specificity of InnowaveDX were 97.1% (95%<i>CI</i>: 93.4%-99.1%) and 99.7% (95%<i>CI</i>: 98.4%-100.0%), respectively, and the kappa value was 0.97 (<i>P</i><0.001). <b>Conclusions:</b> InnowaveDX show a high sensitivity for detecting <i>Mycobacterium tuberculosis</i>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"658-663"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Postpartum fatal pulmonary embolism with F5 gene mutation: a case report].","authors":"R N Zhang,&nbsp;C Y Kong,&nbsp;X Y Chen,&nbsp;K J Ying","doi":"10.3760/cma.j.cn112147-20230417-00181","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20230417-00181","url":null,"abstract":"<p><p>Pulmonary embolism (PE) is one of the leading causes of maternal death. Various clinical and environmental risk factors can cause PE. Here, we reported an uncommon PE case with multiple etiological causes, including caesarean section, overweight, anti-cardiolipin antibody positive, and factor 5 gene mutation. The patient was a 25-year-old woman who developed cardiac asystole and apnea one day after cesarean delivery due to pulmonary embolism. After cardiopulmonary resuscitation and thrombolytic therapy, high doses of epinephrine were still needed to maintain blood pressure and heart rate, so we treated her with venoarterial extracorporeal membrane oxygenation (ECMO) to maintain systemic circulation. She progressively improved and was discharged on oral warfarin treatment. Comprehensive laboratory tests revealed a positive anticardiolipin antibody. Through whole exon gene sequencing, we identified a novel mutation (A2032➝G) in the F5 gene. This mutation was predicted to result in the replacement of lysine with glutamate at position 678, close to one of the APC cleavage sites. P.Lys678Glu was found to be a detrimental mutation by SIFT software and suspected detrimental by Polyphen-2 software. Attention should be paid to the etiological screening of young patients with pulmonary embolism, which is helpful in guiding the anticoagulant scheme and anticoagulant duration, and is of great significance in preventing thrombosis recurrence and complications.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"708-711"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9745886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Endovascular embolization hemoptysis in a patient with coronary artery as non-bronchial systemic artery: a case report].","authors":"X Q Li,&nbsp;X J Yang","doi":"10.3760/cma.j.cn112147-20221128-00930","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20221128-00930","url":null,"abstract":"<p><p>The coronary artery as a responsible vessel for hemoptysis is very rare. This patient was admitted to the hospital with bronchiectasis and hemoptysis, and the right coronary artery was found to be one of the non-bronchial systemic arteries by computed tomography angiography, and the hemoptysis stopped immediately after successful embolization of all bronchial arteries and non-bronchial systemic arteries by bronchial artery embolization. However, the patient had a recurrence of a small amount of hemoptysis 1 month and 3 months after surgery. The patient underwent lobectomy of the lesion after multidisciplinary discussion and did not have any hemoptysis after surgery.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"711-713"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9752046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression and protective effect of chemerin in idiopathic pulmonary fibrosis].","authors":"C Y Shen,&nbsp;G R Li,&nbsp;D Wei,&nbsp;W Wang,&nbsp;X S Yang,&nbsp;C Jiang,&nbsp;Y T Sheng,&nbsp;Z K Yang,&nbsp;X W Nie,&nbsp;J Y Chen","doi":"10.3760/cma.j.cn112147-20221119-00910","DOIUrl":"https://doi.org/10.3760/cma.j.cn112147-20221119-00910","url":null,"abstract":"<p><p><b>Objective:</b> To explore the expression and the role of chemerin in idiopathic pulmonary fibrosis (IPF). <b>Methods:</b> Quantitative PCR and Western blotting were used to determine the mRNA and protein levels of chemerin in lung tissues from IPF patients and the controls. Clinical serum level of chemerin was analyzed by enzyme-linked immunosorbent assay. The mouse lung fibroblasts isolated and cultured <i>in vitro</i> were divided into the control, TGF-β, TGF-β+chemerin and chemerin groups. Immunofluorescence staining was used to observe the expression of α-smooth muscle actin (α-SMA). C57BL/6 mice were randomly divided into the control, bleomycin, bleomycin+chemerin, and chemerin groups. Masson and immunohistochemical staining were performed to evaluate the severity of pulmonary fibrosis. Expression of epithelial to mesenchymal transition (EMT) markers was detected by quantitative PCR and immunohistochemical staining in the <i>in vitro</i> and <i>in vivo</i> models of pulmonary fibrosis, respectively. <b>Results:</b> Compared with the control group, the expression of chemerin was downregulated in both the lung tissue and the serum of IPF patients. Immunofluorescence showed that treatment of fibroblasts with TGF-β alone resulted in a robust expression of α-SMA, whereas treatment with TGF-β and chemerin together exhibited the similar expression levels of α-SMA as the control group. Masson staining indicated that the bleomycin-induced pulmonary fibrosis model was constructed successfully, while treatment of chemerin partially alleviated the damage of lung tissue. Immunohistochemical staining showed that the expression of chemerin in the lung tissue was significantly decreased in the bleomycin group. Quantitative PCR and immunohistochemistry showed that chemerin attenuated EMT induced by TGF-β and bleomycin both <i>in vitro</i> and <i>in vivo</i>. <b>Conclusions:</b> The expression of chemerin was reduced in patients with IPF. Chemerin may play a protective role in the development of IPF by regulating EMT, providing a new idea for the clinical treatment of IPF.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 7","pages":"688-696"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}